tiprankstipranks
Trending News
More News >
Penumbra Inc. (PEN)
:PEN
US Market
Advertisement

Penumbra (PEN) Stock Forecast & Price Target

Compare
450 Followers
See the Price Targets and Ratings of:

PEN Analyst Ratings

Moderate Buy
18Ratings
Moderate Buy
13 Buy
5 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Penumbra
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PEN Stock 12 Month Forecast

Average Price Target

$309.20
▲(21.63%Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Penumbra in the last 3 months. The average price target is $309.20 with a high forecast of $350.00 and a low forecast of $265.00. The average price target represents a 21.63% change from the last price of $254.21.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"170":"$170","351":"$351","215.25":"$215.3","260.5":"$260.5","305.75":"$305.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":350,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$350.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":309.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$309.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":265,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$265.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[170,215.25,260.5,305.75,351],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,250.68,258.32,265.96,273.6,281.24,288.88,296.52,304.16,311.8,319.44,327.08,334.72,342.36,{"y":350,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,250.68,255.18153846153848,259.68307692307695,264.18461538461537,268.68615384615384,273.1876923076923,277.6892307692308,282.1907692307692,286.6923076923077,291.19384615384615,295.6953846153846,300.19692307692304,304.6984615384615,{"y":309.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,250.68,251.78153846153847,252.88307692307694,253.98461538461538,255.08615384615385,256.1876923076923,257.28923076923076,258.39076923076925,259.4923076923077,260.59384615384613,261.6953846153846,262.79692307692306,263.89846153846156,{"y":265,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":177.09,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.25,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":233.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":237.48,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":266.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":285.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250.68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$350.00Average Price Target$309.20Lowest Price Target$265.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on PEN
TipRanks AITipRanks
Not Ranked
TipRanks
$286
Buy
12.51%
Upside
Upgraded
07/31/25
Penumbra's overall stock score of 75 reflects its strong financial performance and positive earnings call insights, highlighting robust revenue growth and successful market execution. However, the high valuation and mixed technical indicators temper the outlook, suggesting caution for potential investors.
Morgan Stanley Analyst forecast on PEN
Patrick WoodMorgan Stanley
Morgan Stanley
$260$266
Hold
4.64%
Upside
Reiterated
07/31/25
Morgan Stanley Remains a Hold on Penumbra (PEN)
UBS
$330$335
Buy
31.78%
Upside
Reiterated
07/31/25
Penumbra price target raised to $335 from $330 at UBSPenumbra price target raised to $335 from $330 at UBS
Truist Financial Analyst forecast on PEN
Richard NewitterTruist Financial
Truist Financial
$300$310
Buy
21.95%
Upside
Reiterated
07/30/25
Truist Financial Reaffirms Their Buy Rating on Penumbra (PEN)
Wells Fargo Analyst forecast on PEN
Larry BiegelsenWells Fargo
Wells Fargo
$315$290
Buy
14.08%
Upside
Reiterated
07/30/25
Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Incyte (NASDAQ: INCY) and Penumbra (NYSE: PEN)
J.P. Morgan Analyst forecast on PEN
Robbie MarcusJ.P. Morgan
J.P. Morgan
$285$265
Hold
4.24%
Upside
Reiterated
07/30/25
Penumbra (PEN) Gets a Hold from J.P. Morgan
Nephron
$305
Buy
19.98%
Upside
Upgraded
07/30/25
Positive Report for Penumbra (PEN) from Nephron
Leerink Partners Analyst forecast on PEN
Mike KratkyLeerink Partners
Leerink Partners
$327
Buy
28.63%
Upside
Reiterated
07/30/25
Penumbra's Strong Growth Potential and Strategic Developments Reinforce Buy RatingWe are reiterating our Outperform rating on PEN and maintaining our $327 PT following the company's 2Q results. PEN reported WW sales +4% vs. consensus, with WW Thrombectomy +1% vs. consensus and WW E&A sales +11% vs. consensus. We were particularly encouraged by another consecutive quarter of strong growth in VTE, with PEN's US VTE business growing +42% y/y. MSD growth of PEN's US Stroke business came in a bit soft, with the company citing flat market growth, though our sense is that expectations were low coming into the print. Notably, PEN announced an expansion of its sales force, including the addition of new E&A reps while existing reps focus more exclusively on PEN's thrombectomy business.
Robert W. Baird Analyst forecast on PEN
David RescottRobert W. Baird
Robert W. Baird
$283$285
Buy
12.11%
Upside
Reiterated
07/30/25
Penumbra price target raised to $285 from $283 at BairdPenumbra price target raised to $285 from $283 at Baird
Canaccord Genuity Analyst forecast on PEN
William PlovanicCanaccord Genuity
Canaccord Genuity
$340$350
Buy
37.68%
Upside
Reiterated
07/30/25
Penumbra price target raised to $350 from $340 at CanaccordPenumbra price target raised to $350 from $340 at Canaccord
RBC Capital
$330$325
Buy
27.85%
Upside
Reiterated
07/30/25
RBC Capital Keeps Their Buy Rating on Penumbra (PEN)RBC Capital analyst Shagun Singh lowered the price target on Penumbra (NYSE: PEN) to $325.00 (from $330.00) while maintaining a Outperform rating.
William Blair Analyst forecast on PEN
Brandon VazquezWilliam Blair
William Blair
Buy
Reiterated
07/30/25
Penumbra's Promising Outlook: Buy Rating Amid Strong Performance and Strategic Growth OpportunitiesWednesday, July 30, 2025 12:59 AM William Blair Equity Research | Healthcare Penumbra, Inc.
BTIG
$320
Buy
25.88%
Upside
Reiterated
07/30/25
BTIG Remains a Buy on Penumbra (PEN)
Needham
Hold
Reiterated
07/30/25
Needham Sticks to Their Hold Rating for Penumbra (PEN)
Jefferies
$325
Buy
27.85%
Upside
Reiterated
07/23/25
Jefferies Reaffirms Their Buy Rating on Penumbra (PEN)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on PEN
TipRanks AITipRanks
Not Ranked
TipRanks
$286
Buy
12.51%
Upside
Upgraded
07/31/25
Penumbra's overall stock score of 75 reflects its strong financial performance and positive earnings call insights, highlighting robust revenue growth and successful market execution. However, the high valuation and mixed technical indicators temper the outlook, suggesting caution for potential investors.
Morgan Stanley Analyst forecast on PEN
Patrick WoodMorgan Stanley
Morgan Stanley
$260$266
Hold
4.64%
Upside
Reiterated
07/31/25
Morgan Stanley Remains a Hold on Penumbra (PEN)
UBS
$330$335
Buy
31.78%
Upside
Reiterated
07/31/25
Penumbra price target raised to $335 from $330 at UBSPenumbra price target raised to $335 from $330 at UBS
Truist Financial Analyst forecast on PEN
Richard NewitterTruist Financial
Truist Financial
$300$310
Buy
21.95%
Upside
Reiterated
07/30/25
Truist Financial Reaffirms Their Buy Rating on Penumbra (PEN)
Wells Fargo Analyst forecast on PEN
Larry BiegelsenWells Fargo
Wells Fargo
$315$290
Buy
14.08%
Upside
Reiterated
07/30/25
Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Incyte (NASDAQ: INCY) and Penumbra (NYSE: PEN)
J.P. Morgan Analyst forecast on PEN
Robbie MarcusJ.P. Morgan
J.P. Morgan
$285$265
Hold
4.24%
Upside
Reiterated
07/30/25
Penumbra (PEN) Gets a Hold from J.P. Morgan
Nephron
$305
Buy
19.98%
Upside
Upgraded
07/30/25
Positive Report for Penumbra (PEN) from Nephron
Leerink Partners Analyst forecast on PEN
Mike KratkyLeerink Partners
Leerink Partners
$327
Buy
28.63%
Upside
Reiterated
07/30/25
Penumbra's Strong Growth Potential and Strategic Developments Reinforce Buy RatingWe are reiterating our Outperform rating on PEN and maintaining our $327 PT following the company's 2Q results. PEN reported WW sales +4% vs. consensus, with WW Thrombectomy +1% vs. consensus and WW E&A sales +11% vs. consensus. We were particularly encouraged by another consecutive quarter of strong growth in VTE, with PEN's US VTE business growing +42% y/y. MSD growth of PEN's US Stroke business came in a bit soft, with the company citing flat market growth, though our sense is that expectations were low coming into the print. Notably, PEN announced an expansion of its sales force, including the addition of new E&A reps while existing reps focus more exclusively on PEN's thrombectomy business.
Robert W. Baird Analyst forecast on PEN
David RescottRobert W. Baird
Robert W. Baird
$283$285
Buy
12.11%
Upside
Reiterated
07/30/25
Penumbra price target raised to $285 from $283 at BairdPenumbra price target raised to $285 from $283 at Baird
Canaccord Genuity Analyst forecast on PEN
William PlovanicCanaccord Genuity
Canaccord Genuity
$340$350
Buy
37.68%
Upside
Reiterated
07/30/25
Penumbra price target raised to $350 from $340 at CanaccordPenumbra price target raised to $350 from $340 at Canaccord
RBC Capital
$330$325
Buy
27.85%
Upside
Reiterated
07/30/25
RBC Capital Keeps Their Buy Rating on Penumbra (PEN)RBC Capital analyst Shagun Singh lowered the price target on Penumbra (NYSE: PEN) to $325.00 (from $330.00) while maintaining a Outperform rating.
William Blair Analyst forecast on PEN
Brandon VazquezWilliam Blair
William Blair
Buy
Reiterated
07/30/25
Penumbra's Promising Outlook: Buy Rating Amid Strong Performance and Strategic Growth OpportunitiesWednesday, July 30, 2025 12:59 AM William Blair Equity Research | Healthcare Penumbra, Inc.
BTIG
$320
Buy
25.88%
Upside
Reiterated
07/30/25
BTIG Remains a Buy on Penumbra (PEN)
Needham
Hold
Reiterated
07/30/25
Needham Sticks to Their Hold Rating for Penumbra (PEN)
Jefferies
$325
Buy
27.85%
Upside
Reiterated
07/23/25
Jefferies Reaffirms Their Buy Rating on Penumbra (PEN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Penumbra

1 Month
xxx
Success Rate
15/21 ratings generated profit
71%
Average Return
+6.68%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +6.68% per trade.
3 Months
xxx
Success Rate
11/18 ratings generated profit
61%
Average Return
+6.43%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +6.43% per trade.
1 Year
Success Rate
14/21 ratings generated profit
67%
Average Return
+16.77%
reiterated a buy rating 2 days ago
Copying Shagun Singh Chadha's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +16.77% per trade.
2 Years
xxx
Success Rate
25/36 ratings generated profit
69%
Average Return
+10.39%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 69.44% of your transactions generating a profit, with an average return of +10.39% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PEN Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
0
0
0
0
0
Buy
16
28
21
22
20
Hold
5
7
6
5
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
35
27
27
28
In the current month, PEN has received 20 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. PEN average Analyst price target in the past 3 months is 309.20.
Each month's total comprises the sum of three months' worth of ratings.

PEN Financial Forecast

PEN Earnings Forecast

Next quarter’s earnings estimate for PEN is $0.92 with a range of $0.85 to $1.03. The previous quarter’s EPS was $0.86. PEN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.06% of the time in the same period. In the last calendar year PEN has Outperformed its overall industry.
Next quarter’s earnings estimate for PEN is $0.92 with a range of $0.85 to $1.03. The previous quarter’s EPS was $0.86. PEN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.06% of the time in the same period. In the last calendar year PEN has Outperformed its overall industry.

PEN Sales Forecast

Next quarter’s sales forecast for PEN is $340.72M with a range of $336.19M to $344.00M. The previous quarter’s sales results were $339.45M. PEN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.32% of the time in the same period. In the last calendar year PEN has Outperformed its overall industry.
Next quarter’s sales forecast for PEN is $340.72M with a range of $336.19M to $344.00M. The previous quarter’s sales results were $339.45M. PEN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.32% of the time in the same period. In the last calendar year PEN has Outperformed its overall industry.

PEN Stock Forecast FAQ

What is PEN’s average 12-month price target, according to analysts?
Based on analyst ratings, Penumbra Inc.’s 12-month average price target is 309.20.
    What is PEN’s upside potential, based on the analysts’ average price target?
    Penumbra Inc. has 21.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PEN a Buy, Sell or Hold?
          Penumbra Inc. has a consensus rating of Moderate Buy which is based on 13 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Penumbra Inc.’s price target?
            The average price target for Penumbra Inc. is 309.20. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $350.00 ,the lowest forecast is $265.00. The average price target represents 21.63% Increase from the current price of $254.21.
              What do analysts say about Penumbra Inc.?
              Penumbra Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of PEN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis